Fig. 3
WRKY family transcription factors are enriched in up-transcribed enhancers. a Significant enrichment (P-value < 0.05) of transcription factors binding motifs in transcribed enhancersA relative to that in non-transcribed enhancersA. b Significant enrichment (P-value < 0.05) of TF binding motifs in upregulated enhancersA relative to that in downregulated enhancersA. The percentage of sequences in the target group versus the background group are displayed to the left of the genes. Enrichment P-values are listed to the right of the genes as −log10 transformed values. c, e–g Average number of W-box motif (TTGACC/T) (c) and ChIP-seq peaks of transcription factors (e–g) in up- or downregulated enhancers, and non-transcribed enhancers. WRKYs binding regions with flg22 treatment for 2 h (e); other differentially enriched TFs binding regions (ASL18, mock; LBD18, mock; NLP4, mock) (f); and other immune TFs binding regions (HD2B, 30 min after flg22 treatment; IDD4, 1 h after flg22 treatment; SARD1, 24 h after Pseudomonas syringae pv. maculicola (P.s.m.) ES4326 treatment) (g). Different letters denote significant differences by the one-way ANOVA test (P-value < 0.05). d Distribution of distances of peaks for ChIP-seq using the anti-all-WRKY antibody at control condition to the nearest enhancer midpoint